Meningococcal polysaccharide vaccines. Recommendation of the Public Health Service Advisory Committee on Immunization Practices, Center for Disease Control, United States Department of Health, Education, and Welfare, Atlanta, Georgia.
Polysaccharide vaccines against diseases caused by Neisseria meningitidis serogroups A and C meningococci are now licensed in the United States. They are prepared as monovalent and as bivalent antigens. This statement summarizes available information on these antigen and offers guidance regarding their role in the control of epidemics of meningococcal disease in the civilian population of the U. S.